ArticleThe American journal of psychiatry2022
Prevalence and Correlates of Cannabis Use and Cannabis Use Disorder Among U.S. Veterans: Results From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III).
Open access · greenAbstract read
In one paragraph
Article in The American journal of psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 32 citations in OpenAlex.
- History of Cannabis Use and Obesity Among U.S. Low-Income Veterans: Associations With Mental Health and Psychosocial Functioning.The Psychiatric quarterly · 2026Article
- Prevalence and trends in cannabis use disorder and cannabis poisoning among Medicaid enrollees: a multistate analysis, 2011-2022.Health affairs scholar · 2025Article
- Cannabis Use Among Older Adults.JAMA network open · 2025Article
- Genome-wide DNA methylation analysis of cannabis use disorder in a veteran cohort enriched for posttraumatic stress disorder.Psychiatry research · 2024Article
- Child Maltreatment History, Deployment-Related Traumatic Events, and Past 12-Month Cannabis Use Among Veterans in Canada.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Article
- Cannabis use disorder contributes to cognitive dysfunction in Veterans with traumatic brain injury.Frontiers in neurology · 2024Article
- Article
- Trends in past-month cannabis use among US adults across a range of disabilities and health conditions, 2015-2019.Preventive medicine · 2023Article
- Cannabis Use Among U.S. Military Veterans Following Residential Substance Use Disorder Treatment.Military medicine · 2023Article
- Prevalence, time trends, and correlates of major depressive episode and other psychiatric conditions among young people amid major social unrest and COVID-19 in Hong Kong: a representative epidemiological study from 2019 to 2022.The Lancet regional health. Western Pacific · 2023Article
- Mental and Physical Health Conditions Among U.S. Veterans with Cannabis Use and Cannabis Use Disorders.Current addiction reports · 2023Article
- Validity of the Single-Item Screen-Cannabis (SIS-C) for Cannabis Use Disorder Screening in Routine Care.JAMA network open · 2022Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Kendall C BrowneCenter of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
Malki StohlCenter of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
Kipling M BohnertCenter of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
Andrew J SaxonCenter of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
David S FinkCenter of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
Mark OlfsonCenter of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
Magdalena CerdaCenter of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
Scott ShermanCenter of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
Jaimie L GradusCenter of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
Silvia S MartinsCenter of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
Deborah S HasinCenter of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
Philadelphia VA Medical Center · US
Funding
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024R01DA048860 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI HASIN, DEBORAH S · 2019 to 2023
$4.1MNIDA NIH HHS R01 DA048860
Abstract
objectiveThe authors sought to estimate the prevalence of past-12-month and lifetime cannabis use and cannabis use disorder among U.S. veterans; to describe demographic, substance use disorder, and psychiatric disorder correlates of nonmedical cannabis use and cannabis use disorder; and to explore differences in cannabis use and cannabis use disorder prevalence among veterans in states with and without medical marijuana laws.
methodsParticipants were 3,119 respondents in the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III) who identified as U.S. veterans. Weighted prevalences were calculated. Logistic regression analyses tested associations of nonmedical cannabis use and cannabis use disorder with demographic and clinical correlates and examined whether prevalence differed by state legalization status.
resultsThe prevalences of any past-12-month cannabis use and cannabis use disorder were 7.3% and 1.8%, respectively. Lifetime prevalences were 32.5% and 5.7%, respectively. Past-12-month and lifetime cannabis use disorder prevalence estimates among nonmedical cannabis users were 24.4% and 17.4%, respectively. Sociodemographic correlates of nonmedical cannabis use and use disorder included younger age, male gender, being unmarried, lower income, and residing in a state with medical marijuana laws. Nonmedical cannabis use and use disorder were associated with most psychiatric and substance use disorders examined.
conclusionsAmong veterans, the odds of nonmedical cannabis use and use disorder were elevated among vulnerable subgroups, including those with lower income or psychiatric disorders and among survey participants residing in states with medical marijuana laws. The study findings highlight the need for clinical attention (e.g., screening, assessment) and ongoing monitoring among veterans in the context of increasing legalization of cannabis.
Indexed as
Alcohol-Related DisordersCannabisHallucinogensMarijuana AbuseMedical MarijuanaSubstance-Related DisordersVeteransEthanolHumansMalePrevalenceUnited StatesEthanolHallucinogensMedical MarijuanaCannabisCannabis Use DisorderNESARC-IIISubstance-Related and Addictive DisordersVeterans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.